The Food and Drug Administration committed to enhanced transparency by releasing complete response letters (CRLs) to drugmakers shortly after issuance, including 89 previously undisclosed letters from 2024 and 2025. The move aligns with public demand for insight into regulatory decisions affecting drug approvals. Notable rejections for companies such as Replimune, Capricor Therapeutics, and Ultragenyx were disclosed. FDA Commissioner Marty Makary emphasized this as a step towards credible, open agency decision-making.